Structure elucidation and total synthesis of a unique group of trace impurities in Tipranavir® drug product

Magnetic Resonance in Chemistry

Volumn 43, Issue 12, 2005, Pages 1032-1039

  Busacca, Carl A ^a   Campbell, Scot ^a   Saha, Anjan ^a   Lorenz, Jon C ^a   Grozinger, Karl ^a   Jones, Paul James ^a   Grinberg, Nelu ^a   Shen, Sherry ^a   Lee, Heewon ^a   Qiu, Fenghe ^a   Granger, Alice ^a   Yuabova, Zhanna ^a   Norwood, Dan ^a   Senanayake, Chris H ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

13C NMR; 1H NMR; COSY; Favorskii; HMBC; HMQC; HRMS; LC MS; NMR; Tipranavir ; TRIS

Indexed keywords

EFFLUENT TREATMENT; GAS CHROMATOGRAPHY; IMPURITIES; SUPERCRITICAL FLUIDS;

13C NMR; 1H NMR; COSY; FAVORSKII; HMBC; HMQC; HRMS; LC/MS; TIPRANAVIR; TIPRANAVIR®; TRIS;

SYNTHESIS (CHEMICAL);

EID: 28644434549     PISSN: 07491581     EISSN: None     Source Type: Journal    
DOI: 10.1002/mrc.1672     Document Type: Article

References (9)

1. (a) Judge TM, Phillips G, Morris JK, Lovasz KD, Romines KR, Luke GP, Tulinsky J, Tustin JM, Chrusciel RA, Dolak LA, Mizsak SA, Watt W, Morris J, Vander Velde SL, Strohbach JW, Gammill RB. J. Am. Chem. Soc. 1997; 119(15): 3627;
2. (b) Martin GE, Pearlman BA, Robins RH, Crow FW, Duholke WK, Guido JE, Hadden CE, Kaluzny BD, Thamann TJ. J. Heterocyclic Chem. 1999; 36: 1107.
3. (a) Yeni P. J. Acquir. Immune Defic. Synd. 2003; 34(Supp.1): S91;
4. (b) Charman SA, Charman WN, Rogge MC, Wilson TD, Dutko FJ, Pouton CW. Pharm. Res. 1992; 9(1): 87.
5. (a) Chenier PJ. J. Chem. Ed. 1978; 55(5): 286;
6. (b) Moulay S. Chem. Ed.: Res. Prac. Eur. 2002; 3(1): 33;
7. (c) Castillo R, Oliva M, Marti S, Moliner V, Tunon I, Andres J. Recent Res. Dev. Quantum Chem. 2002; 3: 51.
8. (a) Christoffers J, Baro A, Werner T. Adv. Syn. Cat. 2004; 346(2 + 3): 143;
9. (b) Gleiter R, Staib M, Ackerman U. Liebigs Ann. Chem. 1995; 9: 1655.